Novo Nordisk's adjusted sales in the third quarter reached 79.2 billion Danish kroner, surpassing expectations

Novo Nordisk's adjusted sales for the third quarter were DKK 79.2 billion, compared to the market expectation of DKK 73.55 billion. Adjusted EBIT for the third quarter was DKK 31.72 billion, with the market expectation at DKK 28.71 billion. Novo Nordisk's adjusted sales of oral Wegovy in the third quarter were DKK 5.39 billion, exceeding the forecast of DKK 4.64 billion. The company expects full-year adjusted sales growth at fixed exchange rates to be between -2% and +2%, with the market anticipating growth of -2.35%.